Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Macrofluidic recirculating model of skeletal metastasis.

Osawa T, Wang W, Dai J, Keller ET.

Sci Rep. 2019 Oct 18;9(1):14979. doi: 10.1038/s41598-019-50577-3.

2.

Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis.

Dai J, Escara-Wilke J, Keller JM, Jung Y, Taichman RS, Pienta KJ, Keller ET.

J Exp Med. 2019 Sep 23. pii: jem.20190158. doi: 10.1084/jem.20190158. [Epub ahead of print]

PMID:
31548301
3.

SNV identification from single-cell RNA sequencing data.

Schnepp PM, Chen M, Keller ET, Zhou X.

Hum Mol Genet. 2019 Aug 27. pii: ddz207. doi: 10.1093/hmg/ddz207. [Epub ahead of print]

PMID:
31504520
4.

Notch3 promotes prostate cancer-induced bone lesion development via MMP-3.

Ganguly SS, Hostetter G, Tang L, Frank SB, Saboda K, Mehra R, Wang L, Li X, Keller ET, Miranti CK.

Oncogene. 2019 Aug 29. doi: 10.1038/s41388-019-0977-1. [Epub ahead of print]

PMID:
31467432
5.

Knockdown of Notch1 inhibits nasopharyngeal carcinoma cell growth and metastasis via downregulation of CCL2, CXCL16, and uPA.

Guo H, Wang F, Diao Y, Zhang Z, Chen Q, Qian CN, Keller ET, Zhang J, Lu Y.

Mol Carcinog. 2019 Oct;58(10):1886-1896. doi: 10.1002/mc.23082. Epub 2019 Jul 3.

PMID:
31270884
6.

Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.

Liang W, Wang F, Chen Q, Dai J, Escara-Wilke J, Keller ET, Zimmermann J, Hong N, Lu Y, Zhang J.

J Cancer Res Clin Oncol. 2019 Aug;145(8):1999-2012. doi: 10.1007/s00432-019-02950-y. Epub 2019 Jun 6.

7.

Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression.

Ahmed AA, Robinson T, Palande M, Escara-Wilke J, Dai J, Keller ET.

J Cell Biochem. 2019 Oct;120(10):16946-16955. doi: 10.1002/jcb.28954. Epub 2019 May 17.

PMID:
31099068
8.

Prostate cancer promotes a vicious cycle of bone metastasis progression through inducing osteocytes to secrete GDF15 that stimulates prostate cancer growth and invasion.

Wang W, Yang X, Dai J, Lu Y, Zhang J, Keller ET.

Oncogene. 2019 Jun;38(23):4540-4559. doi: 10.1038/s41388-019-0736-3. Epub 2019 Feb 12.

PMID:
30755731
9.

A surgical orthotopic approach for studying the invasive progression of human bladder cancer.

Lorenzatti Hiles G, Cates AL, El-Sawy L, Day KC, Broses LJ, Han AL, Briggs HL, Emamdjomeh A, Chou A, Abel EV, Liebert M, Palmbos PL, Udager AM, Keller ET, Day ML.

Nat Protoc. 2019 Mar;14(3):738-755. doi: 10.1038/s41596-018-0112-8.

10.

Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines.

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balaj L, Baldacchino S, Bauer NN, Baxter AA, Bebawy M, Beckham C, Bedina Zavec A, Benmoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobis-Wozowicz S, Boilard E, Boireau W, Bongiovanni A, Borràs FE, Bosch S, Boulanger CM, Breakefield X, Breglio AM, Brennan MÁ, Brigstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-Górecka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buzás EI, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Cocucci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescitelli R, Criado MF, D'Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, De Santana EF, De Wever O, Del Portillo HA, Demaret T, Deville S, Devitt A, Dhondt B, Di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte FV, Duncan HM, Eichenberger RM, Ekström K, El Andaloussi S, Elie-Caille C, Erdbrügger U, Falcón-Pérez JM, Fatima F, Fish JE, Flores-Bellver M, Försönits A, Frelet-Barrand A, Fricke F, Fuhrmann G, Gabrielsson S, Gámez-Valero A, Gardiner C, Gärtner K, Gaudin R, Gho YS, Giebel B, Gilbert C, Gimona M, Giusti I, Goberdhan DC, Görgens A, Gorski SM, Greening DW, Gross JC, Gualerzi A, Gupta GN, Gustafson D, Handberg A, Haraszti RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holthofer H, Hosseinkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AG, Ikezu T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khomyakova E, Khvorova A, Kierulf P, Kim KP, Kislinger T, Klingeborn M, Klinke DJ 2nd, Kornek M, Kosanović MM, Kovács ÁF, Krämer-Albers EM, Krasemann S, Krause M, Kurochkin IV, Kusuma GD, Kuypers S, Laitinen S, Langevin SM, Languino LR, Lannigan J, Lässer C, Laurent LC, Lavieu G, Lázaro-Ibáñez E, Le Lay S, Lee MS, Lee YXF, Lemos DS, Lenassi M, Leszczynska A, Li IT, Liao K, Libregts SF, Ligeti E, Lim R, Lim SK, Linē A, Linnemannstöns K, Llorente A, Lombard CA, Lorenowicz MJ, Lörincz ÁM, Lötvall J, Lovett J, Lowry MC, Loyer X, Lu Q, Lukomska B, Lunavat TR, Maas SL, Malhi H, Marcilla A, Mariani J, Mariscal J, Martens-Uzunova ES, Martin-Jaular L, Martinez MC, Martins VR, Mathieu M, Mathivanan S, Maugeri M, McGinnis LK, McVey MJ, Meckes DG Jr, Meehan KL, Mertens I, Minciacchi VR, Möller A, Møller Jørgensen M, Morales-Kastresana A, Morhayim J, Mullier F, Muraca M, Musante L, Mussack V, Muth DC, Myburgh KH, Najrana T, Nawaz M, Nazarenko I, Nejsum P, Neri C, Neri T, Nieuwland R, Nimrichter L, Nolan JP, Nolte-'t Hoen EN, Noren Hooten N, O'Driscoll L, O'Grady T, O'Loghlen A, Ochiya T, Olivier M, Ortiz A, Ortiz LA, Osteikoetxea X, Østergaard O, Ostrowski M, Park J, Pegtel DM, Peinado H, Perut F, Pfaffl MW, Phinney DG, Pieters BC, Pink RC, Pisetsky DS, Pogge von Strandmann E, Polakovicova I, Poon IK, Powell BH, Prada I, Pulliam L, Quesenberry P, Radeghieri A, Raffai RL, Raimondo S, Rak J, Ramirez MI, Raposo G, Rayyan MS, Regev-Rudzki N, Ricklefs FL, Robbins PD, Roberts DD, Rodrigues SC, Rohde E, Rome S, Rouschop KM, Rughetti A, Russell AE, Saá P, Sahoo S, Salas-Huenuleo E, Sánchez C, Saugstad JA, Saul MJ, Schiffelers RM, Schneider R, Schøyen TH, Scott A, Shahaj E, Sharma S, Shatnyeva O, Shekari F, Shelke GV, Shetty AK, Shiba K, Siljander PR, Silva AM, Skowronek A, Snyder OL 2nd, Soares RP, Sódar BW, Soekmadji C, Sotillo J, Stahl PD, Stoorvogel W, Stott SL, Strasser EF, Swift S, Tahara H, Tewari M, Timms K, Tiwari S, Tixeira R, Tkach M, Toh WS, Tomasini R, Torrecilhas AC, Tosar JP, Toxavidis V, Urbanelli L, Vader P, van Balkom BW, van der Grein SG, Van Deun J, van Herwijnen MJ, Van Keuren-Jensen K, van Niel G, van Royen ME, van Wijnen AJ, Vasconcelos MH, Vechetti IJ Jr, Veit TD, Vella LJ, Velot É, Verweij FJ, Vestad B, Viñas JL, Visnovitz T, Vukman KV, Wahlgren J, Watson DC, Wauben MH, Weaver A, Webber JP, Weber V, Wehman AM, Weiss DJ, Welsh JA, Wendt S, Wheelock AM, Wiener Z, Witte L, Wolfram J, Xagorari A, Xander P, Xu J, Yan X, Yáñez-Mó M, Yin H, Yuana Y, Zappulli V, Zarubova J, Žėkas V, Zhang JY, Zhao Z, Zheng L, Zheutlin AR, Zickler AM, Zimmermann P, Zivkovic AM, Zocco D, Zuba-Surma EK.

J Extracell Vesicles. 2018 Nov 23;7(1):1535750. doi: 10.1080/20013078.2018.1535750. eCollection 2018.

11.

Prostate cancer tends to metastasize in the bone-mimicking microenvironment via activating NF-κB signaling.

Tong HB, Zou CL, Qin SY, Meng J, Keller ET, Zhang J, Lu Y.

J Biomed Res. 2018 Sep 29;32(5):343-353. doi: 10.7555/JBR.32.20180035.

12.

Novel CIL-102 derivatives as potential therapeutic agents for docetaxel-resistant prostate cancer.

Miller DR, Tzeng CC, Farmer T, Keller ET, Caplan S, Chen YS, Chen YL, Lin MF.

Cancer Lett. 2018 Nov 1;436:96-108. doi: 10.1016/j.canlet.2018.07.039. Epub 2018 Aug 3.

13.

Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.

Hovelson DH, Udager AM, McDaniel AS, Grivas P, Palmbos P, Tamura S, Lazo de la Vega L, Palapattu G, Veeneman B, El-Sawy L, Sadis SE, Morgan TM, Montgomery JS, Weizer AZ, Day KC, Neamati N, Liebert M, Keller ET, Day ML, Mehra R, Tomlins SA.

Eur Urol. 2018 Dec;74(6):741-753. doi: 10.1016/j.eururo.2018.06.047. Epub 2018 Jul 20.

PMID:
30033047
14.

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines.

Machioka K, Izumi K, Kadono Y, Iwamoto H, Naito R, Makino T, Kadomoto S, Natsagdorj A, Keller ET, Zhang J, Mizokami A.

Oncotarget. 2018 Mar 5;9(22):16185-16196. doi: 10.18632/oncotarget.24609. eCollection 2018 Mar 23.

15.

Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.

Takezawa Y, Izumi K, Machioka K, Iwamoto H, Naito R, Makino T, Kadomoto S, Natsagdorj A, Kadono Y, Keller ET, Zhang J, Mizokami A.

Anticancer Res. 2018 Apr;38(4):2045-2055.

PMID:
29599322
16.

Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone.

Roca H, Jones JD, Purica MC, Weidner S, Koh AJ, Kuo R, Wilkinson JE, Wang Y, Daignault-Newton S, Pienta KJ, Morgan TM, Keller ET, Nör JE, Shea LD, McCauley LK.

J Clin Invest. 2018 Jan 2;128(1):248-266. doi: 10.1172/JCI92466. Epub 2017 Nov 27.

17.

Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.

Park SH, Keller ET, Shiozawa Y.

Calcif Tissue Int. 2018 Feb;102(2):152-162. doi: 10.1007/s00223-017-0350-8. Epub 2017 Nov 1. Review.

18.

An integrative model of prostate cancer interaction with the bone microenvironment.

Farhat A, Jiang D, Cui D, Keller ET, Jackson TL.

Math Biosci. 2017 Dec;294:1-14. doi: 10.1016/j.mbs.2017.09.005. Epub 2017 Sep 14.

19.

Cytotoxic necrotizing factor 1 promotes prostate cancer progression through activating the Cdc42-PAK1 axis.

Guo Y, Zhang Z, Wei H, Wang J, Lv J, Zhang K, Keller ET, Yao Z, Wang Q.

J Pathol. 2017 Oct;243(2):208-219. doi: 10.1002/path.4940. Epub 2017 Aug 29.

20.

Fibulin-3 promotes muscle-invasive bladder cancer.

Han AL, Veeneman BA, El-Sawy L, Day KC, Day ML, Tomlins SA, Keller ET.

Oncogene. 2017 Sep 14;36(37):5243-5251. doi: 10.1038/onc.2017.149. Epub 2017 May 15.

PMID:
28504717
21.

Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.

Wang W, Wang L, Mizokami A, Shi J, Zou C, Dai J, Keller ET, Lu Y, Zhang J.

Chin J Cancer. 2017 Mar 29;36(1):35. doi: 10.1186/s40880-017-0203-x.

22.

Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression.

Jiang Y, Dai J, Yao Z, Shelley G, Keller ET.

Mol Cancer Res. 2017 Jul;15(7):875-883. doi: 10.1158/1541-7786.MCR-16-0447. Epub 2017 Mar 17.

23.

Immune mediators in the tumor microenvironment of prostate cancer.

Dai J, Lu Y, Roca H, Keller JM, Zhang J, McCauley LK, Keller ET.

Chin J Cancer. 2017 Mar 14;36(1):29. doi: 10.1186/s40880-017-0198-3. Review.

24.

Litchi seed extracts diminish prostate cancer progression via induction of apoptosis and attenuation of EMT through Akt/GSK-3β signaling.

Guo H, Luo H, Yuan H, Xia Y, Shu P, Huang X, Lu Y, Liu X, Keller ET, Sun D, Deng J, Zhang J.

Sci Rep. 2017 Jan 30;7:41656. doi: 10.1038/srep41656.

25.

Metformin targets multiple signaling pathways in cancer.

Lei Y, Yi Y, Liu Y, Liu X, Keller ET, Qian CN, Zhang J, Lu Y.

Chin J Cancer. 2017 Jan 26;36(1):17. doi: 10.1186/s40880-017-0184-9. Review.

26.

Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.

Zhang M, Osisami M, Dai J, Keller JM, Escara-Wilke J, Mizokami A, Keller ET.

Mol Cancer Res. 2017 Apr;15(4):457-466. doi: 10.1158/1541-7786.MCR-16-0392. Epub 2017 Jan 13.

27.

Raman microscopy of bladder cancer cells expressing green fluorescent protein.

Mandair GS, Han AL, Keller ET, Morris MD.

J Biomed Opt. 2016 Nov 1;21(11):115001. doi: 10.1117/1.JBO.21.11.115001.

28.

Providing prostate cancer survivorship care in Japan: Implications from the USA care model.

Osawa T, Wittmann D, Jimbo M, Keller ET, Namiki S, Abe T, Shinohara N, Skolarus TA.

Int J Urol. 2016 Nov;23(11):906-915. doi: 10.1111/iju.13186. Epub 2016 Sep 13. Review.

29.

IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker.

Chen Q, Qin S, Liu Y, Hong M, Qian CN, Keller ET, Zhang J, Lu Y.

Oncotarget. 2016 Oct 18;7(42):68140-68150. doi: 10.18632/oncotarget.11886.

30.

Snail/Slug binding interactions with YAP/TAZ control skeletal stem cell self-renewal and differentiation.

Tang Y, Feinberg T, Keller ET, Li XY, Weiss SJ.

Nat Cell Biol. 2016 Sep;18(9):917-29. doi: 10.1038/ncb3394. Epub 2016 Aug 1.

31.

Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622.

Schott AF, Barlow WE, Van Poznak CH, Hayes DF, Moinpour CM, Lew DL, Dy PA, Keller ET, Keller JM, Hortobagyi GN.

Breast Cancer Res Treat. 2016 Aug;159(1):87-95. doi: 10.1007/s10549-016-3911-z. Epub 2016 Jul 30.

32.

Exosome-derived microRNAs contribute to prostate cancer chemoresistance.

Li J, Yang X, Guan H, Mizokami A, Keller ET, Xu X, Liu X, Tan J, Hu L, Lu Y, Zhang J.

Int J Oncol. 2016 Aug;49(2):838-46. doi: 10.3892/ijo.2016.3560. Epub 2016 Jun 3.

PMID:
27278879
33.

Skp2 is associated with paclitaxel resistance in prostate cancer cells.

Yang Y, Lu Y, Wang L, Mizokami A, Keller ET, Zhang J, Fu J.

Oncol Rep. 2016 Jul;36(1):559-66. doi: 10.3892/or.2016.4809. Epub 2016 May 13.

PMID:
27175797
34.

Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis.

Yang T, Yao H, He G, Song L, Liu N, Wang Y, Yang Y, Keller ET, Deng X.

J Cancer. 2016 Jan 1;7(2):192-9. doi: 10.7150/jca.13414. eCollection 2016.

35.

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.

Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM.

Neoplasia. 2016 Jan;18(1):1-9. doi: 10.1016/j.neo.2015.11.009.

36.

Translational progress on tumor biomarkers.

Guo H, Zhou X, Lu Y, Xie L, Chen Q, Keller ET, Liu Q, Zhou Q, Zhang J.

Thorac Cancer. 2015 Nov;6(6):665-71. doi: 10.1111/1759-7714.12294. Epub 2015 Jul 27. Review.

37.

Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.

Chen F, Dai Z, Kang Y, Lv G, Keller ET, Jiang Y.

Osteoporos Int. 2016 Apr;27(4):1469-1476. doi: 10.1007/s00198-015-3398-1. Epub 2015 Nov 10.

38.

Wnt3a: functions and implications in cancer.

He S, Lu Y, Liu X, Huang X, Keller ET, Qian CN, Zhang J.

Chin J Cancer. 2015 Sep 14;34(12):554-62. doi: 10.1186/s40880-015-0052-4. Review.

39.

Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.

Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET.

Clin Cancer Res. 2015 Oct 15;21(20):4619-29. doi: 10.1158/1078-0432.CCR-15-0242. Epub 2015 Jul 22.

40.

Role of Runx2 phosphorylation in prostate cancer and association with metastatic disease.

Ge C, Zhao G, Li Y, Li H, Zhao X, Pannone G, Bufo P, Santoro A, Sanguedolce F, Tortorella S, Mattoni M, Papagerakis S, Keller ET, Franceschi RT.

Oncogene. 2016 Jan 21;35(3):366-76. doi: 10.1038/onc.2015.91. Epub 2015 Apr 13.

41.

Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases.

Sottnik JL, Dai J, Zhang H, Campbell B, Keller ET.

Cancer Res. 2015 Jun 1;75(11):2151-8. doi: 10.1158/0008-5472.CAN-14-2493. Epub 2015 Apr 8.

42.

Survey of Raf kinase inhibitor protein (RKIP) in multiple cancer types.

Lamiman K, Keller JM, Mizokami A, Zhang J, Keller ET.

Crit Rev Oncog. 2014;19(6):455-68. Review.

PMID:
25597355
43.

Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer.

Wang JQ, DeChalus A, Chatterjee DN, Keller ET, Mizokami A, Camussi G, Mendelsohn AR, Renzulli Ii JF, Quesenberry PJ, Chatterjee D.

Crit Rev Oncog. 2015;20(5-6):407-17. doi: 10.1615/CritRevOncog.v20.i5-6.120. Review.

44.

Targeting the Notch signaling pathway in cancer therapeutics.

Guo H, Lu Y, Wang J, Liu X, Keller ET, Liu Q, Zhou Q, Zhang J.

Thorac Cancer. 2014 Nov;5(6):473-86. doi: 10.1111/1759-7714.12143. Epub 2014 Oct 23. Review.

45.

Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.

Escara-Wilke J, Keller JM, Ignatoski KM, Dai J, Shelley G, Mizokami A, Zhang J, Yeung ML, Yeung KC, Keller ET.

Prostate. 2015 Feb 15;75(3):292-302. doi: 10.1002/pros.22915. Epub 2014 Oct 18.

46.

Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow.

Jung Y, Wang J, Lee E, McGee S, Berry JE, Yumoto K, Dai J, Keller ET, Shiozawa Y, Taichman RS.

Mol Cancer Res. 2015 Jan;13(1):197-207. doi: 10.1158/1541-7786.MCR-14-0118. Epub 2014 Aug 19.

47.

Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis.

Soki FN, Koh AJ, Jones JD, Kim YW, Dai J, Keller ET, Pienta KJ, Atabai K, Roca H, McCauley LK.

J Biol Chem. 2014 Aug 29;289(35):24560-72. doi: 10.1074/jbc.M114.571620. Epub 2014 Jul 8.

48.

Mangiferin attenuates TH1/TH2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model.

Guo HW, Yun CX, Hou GH, Du J, Huang X, Lu Y, Keller ET, Zhang J, Deng JG.

PLoS One. 2014 Jun 23;9(6):e100394. doi: 10.1371/journal.pone.0100394. eCollection 2014.

49.

SOD3 acts as a tumor suppressor in PC-3 prostate cancer cells via hydrogen peroxide accumulation.

Kim J, Mizokami A, Shin M, Izumi K, Konaka H, Kadono Y, Kitagawa Y, Keller ET, Zhang J, Namiki M.

Anticancer Res. 2014 Jun;34(6):2821-31.

PMID:
24922645
50.

IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer.

Sun X, Mao Y, Wang J, Zu L, Hao M, Cheng G, Qu Q, Cui D, Keller ET, Chen X, Shen K, Wang J.

Oncogene. 2014 Jun 9. doi: 10.1038/onc.2014.158. Epub 2014 Jun 9. Retraction in: Oncogene. 2014 Aug 28;33(35):4450.

PMID:
24909173

Supplemental Content

Loading ...
Support Center